A number of researchers and pharmaceutical companies have investigated antibody treatments that block the PD-1/PD-L1 pathway in humans, and anti-PD-1 and anti-PD-L1 antibodies have been approved for various human cancers or evaluated in clinical trials (7–11, 46). The gene discussed is CD274; the disease is cancer.